Skip to main content
SpringerLink
Log in

Hirntumoren

Diagnose und Therapie der Gliome des Erwachsenen

  • Zertifizierte Fortbildung
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

© Markus GroßBasel

2

© Markus GroßBasel

3

© Markus GroßBasel

5

© Markus GroßBasel

2

© Markus GroßBasel

3

© Markus GroßBasel

4

© Markus GroßBasel

Literatur

  1. Ostrom QT et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17 Suppl 4(Suppl 4):iv1-iv62

  2. Louis DN et al. WHO classification of tumours of the central nervous system, Revised 4th ed. Lyon: IARC 2016;10-122

  3. Hegi ME et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003

  4. Macdonald DR et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-80

  5. Wen PY et al. Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol. 2017;35(21): 2439-49

  6. Brandsma D et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9(5):453-61

  7. MoCA Test. https://www.mocatest.org/pdf_files/test/MOCA-Test-German2.pdf abgerufen am 10. September 2020

  8. Stummer W et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392-401

  9. Walker MD et al. An Analysis of Dose-Effect Relationship in the Radiotherapy of Malignant Gliomas. Int J Radiat Oncol Biol Phys 1979;5(10):1725-1731

  10. Shrieve DC et al. Treatment of Patients With Primary Glioblastoma Multiforme With Standard Postoperative Radiotherapy and Radiosurgical Boost: Prognostic Factors and Long-Term Outcome. J Neurosurg. 1999;90(1):72-77

  11. Roa W et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583-1588

  12. Baumert BG et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17(11):1521-32

  13. van den Bent et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985-90

  14. Niyazi M et al. ESTRO-ACROP Guideline "Target Delineation of Glioblastomas". Radiother Oncol. 2016;118(1):35-42

  15. Stupp R et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96

  16. Wick W et al. Long-term Analysis of the NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide. Neuro Oncol. 2016;18(11):1529-37

  17. Taal W et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15:943-53

  18. Lubelski D et al. Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature. J Neurooncol. 2013;115:317-22

  19. Stupp R et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. A Randomized Clinical Trial. JAMA. 2017;318(23):2306-16

  20. Reardon DA et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(7):1003-1010

  21. Buckner JC et al. Radiation plus procarbazine, CCNU, and vincristine in Low-Grade Glioma. N Engl J Med. 2016;374:1344-55

  22. van den Bent MJ et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344-50

  23. van den Bent MJ et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 2017;390:1645-53

  24. Herrlinger U et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019;393(10172):678-88

  25. Perry JR et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376:1027-37

Download references

Author information

Authors and Affiliations

  1. Klinik für Strahlentherapie und Radioonkologie, Universitätsspital Basel, Petersgraben 4, 4031, Basel, Schweiz

    Markus W. Groß

Authors
  1. Markus W. Groß
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Der Autor erklärt, dass er sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen leiten ließ. Der Autor legt folgende potenzielle Interessenkonflikte offen: keine

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Groß, M. Diagnose und Therapie der Gliome des Erwachsenen. InFo Hämatol Onkol 23, 65–75 (2020). https://doi.org/10.1007/s15004-020-8237-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-020-8237-7

Search

Navigation